Actinium Pharmaceuticals, Inc.

Actinium is headquartered in the United States and its current operating footprint is centered on U.S.-based clinical development, manufacturing planning, and regulatory interactions. The company retains commercialization rights for Iomab-B in the U.S. and the rest of the world, while Immedica holds exclusive rights in certain EUMENA countries. Its clinical and research network includes major U.S. cancer hospitals and U.S. government collaborators, which makes domestic regulatory execution especially important. Internationally, the company has patent coverage in Canada, Europe, and Japan, and its future commercial model may rely on territory-by-territory partnering outside the U.S.

Actinium is a clinical-stage company with no commercial product revenue, so its business depends on successful trial outcomes, regulatory approvals, and financing access. Development risk is high because radiotherapeutics are complex to manufacture, ship, and administer, and the company relies on short-lived isotopes that must be delivered just in time. Regulatory delays, including FDA or NIH disruptions and government shutdowns, can slow trials and grant-funded work, while competition from other biotech and pharma companies may reduce partnering or commercialization opportunities. The company also faces patent uncertainty, hazardous-material handling risk, and execution risk around building its own Ac-225 manufacturing capability and retaining specialized personnel.